Tremfya Demonstrates Superiority Over Cosentyx in Ph III Data in Moderate to Severe Plaque Psoriasis

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the ECLIPSE study demonstrating that Tremfya (guselkumab) was superior to Cosentyx (secukinumab)* in treating adults with moderate to severe plaque psoriasis for the primary endpoint assessed at week 48.